KI-67 as a predictive indicator of papillary thyroid cancer in Iraqi patients

BACKGROUND. KI-67 (MKI-67 in humans) is a protein able to bind to DNA which contributes to cell growth and cell proliferation. KI-67 is currently considered as a biomarker that is widely utilized as prognostic indicator for evaluating cell proliferation, diagnosing diseases, and conducting research. Several different kinds of cancer have high Ki-67 expression, which simplifying the choice of treatment for individuals with various cancer types.
AIM. The objective was to evaluate the expression of KI67 in patients suffering papillary thyroid cancer (PTC) also the association between patients age and gender and KI67 expression.
MATERIALS AND METHODS. To undertake an in-depth investigation of KI67 in malignant and normal tissues, we used thyroid tissue sections to analyze KI67 expression in 70 samples, 50 different PTC (44 female and 6 male), and 20 normal types (10 for each gender). Each group’s average age is between 20 and 60.
RESULTS. The analysis of the data revealed a substantial difference in the expression of ki67 between the patients and control groups. Ki67 expression and either gender or age did not significantly correlate.
CONCLUSION. This study suggest that KI67 may be a crucial marker for assessing the aggressiveness of tumors and inflammatory diseases.

1. Khachatryan MA, Mkhitaryan LM. Papillary thyroid cancer, Hashimoto’s thyroiditis, adenomatoid hyperplasia. Do they have any connection? Problems of Endocrinology. 2016;62(5):55-56. doi: https://doi.org/10.14341/probl201662555-56

2. Doubi A, Al-Qannass A, Al-Angari SS, Al-Qahtani KH, Alessa M, Al-Dhahri S. Trends in thyroid carcinoma among thyroidectomy patients: A 12-year multicenter study. Ann Saudi Med. 2019. doi: https://doi.org/10.5144/0256-4947.2019.345

3. Lloyd RV, Osamura RY, Kloppel G, et al. WHO classification of tumours of endocrine organs. Lyon: (IARC). 2017. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Endocrine-Organs-2017

4. Mao J, Zhang Q, Zhang H, Zheng K, Wang R, Wang G. Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2020;11. doi: https://doi.org/10.3389/fendo.2020.00265

5. Dwivedi SS. Study of Immunohistochemical Markers (CK-19, CD-56, Ki-67, p53) in Differentiating Benign and Malignant Solitary Thyroid Nodules with special Reference to Papillary Thyroid Carcinomas. J Clin DIAGNOSTIC Res. 2016. doi: https://doi.org/10.7860/JCDR/2016/22428.9114

6. LI LT, JIANG G, CHEN Q, ZHENG JN. Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol Med Rep. 2015;11(3):1566-1572. doi: https://doi.org/10.3892/mmr.2014.2914

7. Lindfors H, Karlsen M, Karlton E, et al. Thyroglobulin expression, Ki-67 index, and lymph node ratio in the prognostic assessment of papillary thyroid cancer. Sci Rep. 2023;13(1):1070. doi: https://doi.org/10.1038/s41598-023-27684-3

8. Somuncu E. What is the meaning of ki67 expression in papillary thyroid cancer? Biomed. Res. 2021:S49-S52. Available from: https://www.alliedacademies.org/articles/what-is-the-meaning-of-ki67-expression-in-papillary-thyroid-cancer.pdf

9. Ahmed S, Rashed H, Hegazy A, Mohamed AM, Elmesallamy W. Prognostic value of aldh1, ezh2 and ki-67 in astrocytic gliomas. Turkish J Pathol. 2016. doi: https://doi.org/10.5146/tjpath.2015.01344

10. Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer. Cancers (Basel). 2021;13(17):4455. doi: https://doi.org/10.3390/cancers13174455

11. MAIA R, SANTOS GA DOS, REIS S, et al. Can we use Ki67 expression to predict prostate cancer aggressiveness? Rev Col Bras Cir. 2022;49. doi: https://doi.org/10.1590/0100-6991e-20223200-en

12. Suhaimi SNA, Shuhaili MA, Isa NM, Puad SHM, Shah SA, Mohammad R. The Missing Link between Ki-67 and Papillary Thyroid Carcinoma. World J Endocr Surg. 2020;12(2):80-85. doi: https://doi.org/10.5005/jp-journals-10002-1287

13. Sun X, Kaufman PD. Ki-67: more than a proliferation marke. Chromosoma. 2018;127(2):175–186. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945335/

14. Remnant L, Kochanova NY, Reid C, Cisneros-Soberanis F, Earnshaw WC. The intrinsically disorderly story of Ki-67. Open Biol. 2021. doi: https://doi.org/10.1098/rsob.210120

15. Zhou Y, Jiang H-G, Lu N, Lu B-H, Chen Z-H. Expression of Ki67 in Papillary Thyroid Microcarcinoma and its Clinical Significance. Asian Pacific J Cancer Prev. 2015;16(4):1605-1608. doi: https://doi.org/10.7314/APJCP.2015.16.4.1605

16. Tran QL, Davies L. Thyroid cancer incidence differences between men and women. Curr Opin Endocr Metab Res. 2023. doi: https://doi.org/10.1016/j.coemr.2023.100472

17. Yu L, Hong H, Han J, Leng SX, Zhang H, Yan X. Comparison of Survival and Risk Factors of Differentiated Thyroid Cancer in the Geriatric Population. Front Oncol. 2020;10. doi: https://doi.org/10.3389/fonc.2020.00042

18. Lei Y, Zhao X, Feng Y, He D, Hu D, Min Y. The Value of Ki-67 Labeling Index in Central Lymph Node Metastasis and Survival of Papillary Thyroid Carcinoma: Evidence From the Clinical and Molecular Analyses. Cancer Control. 2023;30. doi: https://doi.org/10.1177/10732748231155701

19. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C. Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer: Increased Ki-67 expression in older patients. Tumor Biol. 2005. doi: https://doi.org/10.1159/000084340

20. Pan DH, Wen DY, Luo YH, et al. The diagnostic and prognostic values of KI-67/ MIB-1 expression in thyroid cancer: A meta-analysis with 6,051 cases. Onco Targets Ther. 2017. doi: https://doi.org/10.2147/OTT.S135593